Having held this stock for 5 years+ I think I can guess on the general tenor of the earnings call.
Continuing to execute on plans to roll out GATTEX and NETPARA.
Moving ahead with GATTEX filings to add pediatric indications.
GATTEX patient enrollment ahead of goals.
NATPARA on track for Q3 or 4 submission for BLA
Sensipar continues to outperform. Non-Recource debt paid off Q1-2 , 2014
A few new compounds coming onto the radar.
NATPARA ahead of filing achedule!
GATTEX enrollment numbers now look to exceed 1000 by Q1 14!
Sensipar royalties growing ao fast we are paying of non-recourse debt early!
Insurance comapnies world-wide add GATTEX to formulary!
Major Pharma in talks with NPSP on potential relationship to enhance shareholder value!!